Q4FY17 Results: Neuland Laboratories Ltd
Amir Shaikh / 12 May 2017
Neuland Laboratories Ltd. reported its results for the quarter ended March 31, 2017.
Neuland Laboratories Ltd. reported its results for the quarter ended March 31, 2017.
The company's total sales for Q3FY17 came in at Rs 140.95 crore, which represents a 6.43 per cent sequential increase and 4.41 per cent YoY increase.
Its operating profit (EBIT) for the quarter amounted to Rs 17.49 crore and its EBIT margin stood at 12.41 per cent.
The company reported PAT of Rs 8.5 crore, which represents a sequential QoQ increase of 123.68 per cent and a YoY increase of 28.79 per cent.
The company's stock at Rs. 1360.4 on the BSE, rose 1.82 per cent to Rs 1370.95. It hit intra-day high and low of Rs 1394.8 and Rs 1343.65, respectively.
Neuland Laboratories Ltd is an India-based pharmaceutical company. The company is engaged on manufacture of APIs, contract research and contract manufacturing. The products of company are Albuterol/Salbutanol sulphate, Aripiprazole, Ciprofloxacin Hydrochoride, Darifenacin Hydriobfomide, Enalapril Maleate etc.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.